Glypican-1 as a biomarker for prostate cancer: Isolation and characterization

Quach Truong, Irene O. Justiniano, Aline L. Nocon, Julie T. Soon, Sandra Wissmueller, Douglas H. Campbell, Bradley J. Walsh*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)
1 Downloads (Pure)

Abstract

Prostate cancer is the most frequently diagnosed male visceral cancer and the second leading cause of cancer death in the United States. Standard tests such as prostate-specific antigen (PSA) measurement have poor specificity (33%) resulting in a high number of false positive reports. Consequently there is a need for new biomarkers to address this problem. The MIL-38 antibody was first described nearly thirty years ago, however, until now, the identification of the target antigen remained elusive. By a series of molecular techniques and mass spectrometry, the MIL-38 antigen was identified to be the highly glycosylated proteoglycan Glypican-1 (GPC-1). This protein is present in two forms; a membrane bound core protein of 55-60 kDa and secreted soluble forms of 40 kDa and 52 kDa. GPC-1 identification was confirmed by immuno-precipitation, western blots and ELISA. An ELISA platform is currently being developed to assess the levels of GPC-1 in normal, benign prostatic hyperplasia (BPH) and prostate cancer patients to determine whether secreted GPC-1 may represent a clinically relevant biomarker for prostate cancer diagnosis.

Original languageEnglish
Pages (from-to)1002-1009
Number of pages8
JournalJournal of Cancer
Volume7
Issue number8
DOIs
Publication statusPublished - 2016
Externally publishedYes

Bibliographical note

Copyright the Publisher. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • Glypican 1
  • Prostate Cancer
  • Proteoglycan
  • Theranostic

Fingerprint Dive into the research topics of 'Glypican-1 as a biomarker for prostate cancer: Isolation and characterization'. Together they form a unique fingerprint.

Cite this